Cargando…

Construction of a Mammalian IRES-based Expression Vector to Amplify a Bispecific Antibody; Blinatumomab

Blinatumomab, the bispecific T cell engager antibody (BsAb), has been demonstrated as the most successful BsAb to date. Throughout the past decade, vector design has great importance for the expression of monoclonal antibody in Chinese hamster ovary (CHO) cells. It has been indicated that expression...

Descripción completa

Detalles Bibliográficos
Autores principales: Naddafi, Fatemeh, Davami, Fatemeh, Tabarzad, Maryam, Barkhordari, Farzaneh, Shirazi, Farshad H.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Shaheed Beheshti University of Medical Sciences 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7059065/
https://www.ncbi.nlm.nih.gov/pubmed/32184875
http://dx.doi.org/10.22037/ijpr.2019.14387.12351
_version_ 1783503972717297664
author Naddafi, Fatemeh
Davami, Fatemeh
Tabarzad, Maryam
Barkhordari, Farzaneh
Shirazi, Farshad H.
author_facet Naddafi, Fatemeh
Davami, Fatemeh
Tabarzad, Maryam
Barkhordari, Farzaneh
Shirazi, Farshad H.
author_sort Naddafi, Fatemeh
collection PubMed
description Blinatumomab, the bispecific T cell engager antibody (BsAb), has been demonstrated as the most successful BsAb to date. Throughout the past decade, vector design has great importance for the expression of monoclonal antibody in Chinese hamster ovary (CHO) cells. It has been indicated that expression vectors based on the elongation factor-1 alpha (EF-1 alpha) gene and DHFR selection marker can be highly effective to produce populations of stably transfected cells in the selection medium. Moreover, the phiC31 integrase system is considered as an attractive and safe protein expression system in mammalian cells and it could integrate a donor plasmid of any size, as a single copy, in to the host genome with no cofactors. In this study, phiC31 integrase technology in combination with DHFR amplification system was used to have an expression vector for future expression of blinatumomab in CHO cells. The gene of interest (BsAb gene) could be joined to DHFR selection marker with the insertion of an internal ribosome entry site (IRES). By positioning the DHFR downstream of BsAb gene and IRES, the transcription of the selection marker can depend on the successful transcription of the BsAb gene, which was located upstream in the expression construct. In this study, FC550A-1 vector was used as the backbone and DHFR selection marker was successfully combined with phiC31 integrase technology to generate a high-expressing construct for BsAb expression in CHO-DG44 cells in future studies.
format Online
Article
Text
id pubmed-7059065
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Shaheed Beheshti University of Medical Sciences
record_format MEDLINE/PubMed
spelling pubmed-70590652020-03-17 Construction of a Mammalian IRES-based Expression Vector to Amplify a Bispecific Antibody; Blinatumomab Naddafi, Fatemeh Davami, Fatemeh Tabarzad, Maryam Barkhordari, Farzaneh Shirazi, Farshad H. Iran J Pharm Res Original Article Blinatumomab, the bispecific T cell engager antibody (BsAb), has been demonstrated as the most successful BsAb to date. Throughout the past decade, vector design has great importance for the expression of monoclonal antibody in Chinese hamster ovary (CHO) cells. It has been indicated that expression vectors based on the elongation factor-1 alpha (EF-1 alpha) gene and DHFR selection marker can be highly effective to produce populations of stably transfected cells in the selection medium. Moreover, the phiC31 integrase system is considered as an attractive and safe protein expression system in mammalian cells and it could integrate a donor plasmid of any size, as a single copy, in to the host genome with no cofactors. In this study, phiC31 integrase technology in combination with DHFR amplification system was used to have an expression vector for future expression of blinatumomab in CHO cells. The gene of interest (BsAb gene) could be joined to DHFR selection marker with the insertion of an internal ribosome entry site (IRES). By positioning the DHFR downstream of BsAb gene and IRES, the transcription of the selection marker can depend on the successful transcription of the BsAb gene, which was located upstream in the expression construct. In this study, FC550A-1 vector was used as the backbone and DHFR selection marker was successfully combined with phiC31 integrase technology to generate a high-expressing construct for BsAb expression in CHO-DG44 cells in future studies. Shaheed Beheshti University of Medical Sciences 2019 /pmc/articles/PMC7059065/ /pubmed/32184875 http://dx.doi.org/10.22037/ijpr.2019.14387.12351 Text en This is an Open Access article distributed under the terms of the Creative Commons Attribution License, (http://creativecommons.org/licenses/by/3.0/) which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Original Article
Naddafi, Fatemeh
Davami, Fatemeh
Tabarzad, Maryam
Barkhordari, Farzaneh
Shirazi, Farshad H.
Construction of a Mammalian IRES-based Expression Vector to Amplify a Bispecific Antibody; Blinatumomab
title Construction of a Mammalian IRES-based Expression Vector to Amplify a Bispecific Antibody; Blinatumomab
title_full Construction of a Mammalian IRES-based Expression Vector to Amplify a Bispecific Antibody; Blinatumomab
title_fullStr Construction of a Mammalian IRES-based Expression Vector to Amplify a Bispecific Antibody; Blinatumomab
title_full_unstemmed Construction of a Mammalian IRES-based Expression Vector to Amplify a Bispecific Antibody; Blinatumomab
title_short Construction of a Mammalian IRES-based Expression Vector to Amplify a Bispecific Antibody; Blinatumomab
title_sort construction of a mammalian ires-based expression vector to amplify a bispecific antibody; blinatumomab
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7059065/
https://www.ncbi.nlm.nih.gov/pubmed/32184875
http://dx.doi.org/10.22037/ijpr.2019.14387.12351
work_keys_str_mv AT naddafifatemeh constructionofamammalianiresbasedexpressionvectortoamplifyabispecificantibodyblinatumomab
AT davamifatemeh constructionofamammalianiresbasedexpressionvectortoamplifyabispecificantibodyblinatumomab
AT tabarzadmaryam constructionofamammalianiresbasedexpressionvectortoamplifyabispecificantibodyblinatumomab
AT barkhordarifarzaneh constructionofamammalianiresbasedexpressionvectortoamplifyabispecificantibodyblinatumomab
AT shirazifarshadh constructionofamammalianiresbasedexpressionvectortoamplifyabispecificantibodyblinatumomab